Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Alcyone Therapeutics, Inc · with Biogen · NCT05866419
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 3+ · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 90
- US sites recruiting
- 15
- Study start
- November 27, 2023
- Record last updated
- August 19, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA).
All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.
Being studied: ThecaFlex DRx System
Conditions: Spinal Muscular Atrophy; Spine Deformity; Scoliosis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Subject is 3 years or older
- Subject is diagnosed with SMA and is a candidate for Spinraza treatment as indicated in country-specific label
- Subject resistant to lumbar puncture (LP), where resistance is defined as:
- Subject with respiratory issues or other comorbidities who is at an increased risk for complications due to the need for repeat anesthesia and imaging radiation exposure to safely perform LP; or
- Subjects for whom the treating physician determines implantation of the ThecaFlex DRx™ System is otherwise in the subject's best interest
- Subject has been prescribed nusinersen via chronic intrathecal bolus administration in accordance with the country-specific drug labeling
- Subject, per Investigator discretion, is able to undergo a percutaneous or open surgical procedure for index port and catheter implantation where at least 7 cm of the ThecaFlex DRx system catheter will be placed intrathecally
- Subject (or subject's legally authorized representative) is willing and able to provide written informed consent; and
- Subject and parent/caregiver able and willing to complete all clinical investigation procedures, measurements, and visits.
Exclusion Criteria
- Subject meets any of the contraindications for use of the ThecaFlex DRx System as outlined in the ThecaFlex DRx System Instructions for Use
- Presence or history of (\< 6 months prior to the procedure): an implanted microinfusion pump, intrathecal catheter, or other intrathecal drug delivery devices/component, or implanted shunt for drainage of cerebrospinal fluid (CSF), or reservoir in the CSF space (note: any ThecaFlex Port and Catheter System must not be placed in the same location as a previous indwelling port and catheter)
- Subject is pregnant or nursing or plans to become pregnant during the course of the clinical investigation, or is a woman of childbearing potential or a man of reproductive age who is unwilling or unable to practice contraception, as described in Section 14.10.
- Any condition or event, which in the opinion of the Investigator may adversely affect the safety and effective implantation and use of the ThecaFlex DRx system or confound the clinical investigation, including:
- Severe structural impediment that may preclude safe implantation of the catheter and port
- Major medical events (as defined per investigator's discretion) within 60 days prior to screening; or
- Relevant surgeries (e.g., head and neck, back, etc.) within 60 days prior to screening or planned during the duration of the clinical investigation
- Space-occupying lesion with mass effect
- Posterior fossa mass
- Arnold-Chiari malformation
- Coagulation abnormalities and/or thrombocytopenia
- Insufficient or inadequate skin or underlying fat to adequately protect the port or enough surface area to allow the skin to close safely
- Subject is contraindicated for administration of nusinersen per its approved country-specific labeling
- History of intrathecal granuloma formation
- History of bacterial meningitis or aseptic meningitis within 6 months of screening
- History of tumors or other spinal abnormalities documented by magnetic resonance imaging (MRI) or computed tomography (CT) that would interfere with the catheter implantation procedures or CSF circulation
- History of hydrocephalus
- Diagnosed degenerative muscular disease other than SMA
- History of depression, cognitive impairment, or another psycho-behavioral problem that in the opinion of the Investigator may preclude safe participation in the clinical investigation and
- Serious medical condition that, in the opinion of the investigator, may lead to reduced life expectancy beyond 12 months.
- Subject is involved in another Investigation Device Exemption Study.
- Subject has clinically meaningful immunosuppression, in the opinion of the investigator, either from therapy or a comorbid condition, which, in the opinion of the investigator, makes them a poor surgical candidate due to increased risk of infection.
Recruiting US locations
Barrow Neurological Institute
Phoenix, AZ 85013
Site contact: Kathleen Nagaran Hildebrand · (602) 406 7031 · kathleen.nagaranhildebrand900@commonspirit.org
Children's Hospital Orange County
Orange, CA 92868
Site contact: Melina Thaxton · MelinaThaxton@choc.org
Stanford Medical Center
Palo Alto, CA 94301
Site contact: Habib Mofakham · neuromuscularresearch@stanford.edu
Rady Children's Hospital
San Diego, CA 92037
Site contact: Elizabeth Moreno · e4moreno@health.ucsd.edu
Nemours Children's Hospital, Florida
Orlando, FL 32827
Site contact: Debbie Berry · debbie.berry@nemours.org
Lurie Childrens Hospital
Chicago, IL 60611
Site contact: Raven HIll
Boston Children's Hospital
Boston, MA 02115
Site contact: Adam Porter · adam.porter@childrens.harvard.edu
Helen DeVos Children's Hospital
Grand Rapids, MI 49503
Site contact: Natasha Schafer · natasha.schafer@corewellhealth.org
Columbia University Irving Medical Center/NewYork Presbyterian Hospital
New York, NY 10032
Site contact: Kimbery Berry · 212-342-3038 · KB2996@cumc.columbia.ediu
UH Rainbow Babies and Children's Hospital
Cleveland, OH 44106
Site contact: Abigail Schlosser · Abigail.Schlosser@UHhospitals.org
Penn State Milton S. Hershey Medical Center
Hershey, PA 17033
Site contact: Chelsea Emrick · awinters2@pennstatehealth.psu.edu
Children's Hospital Philadelphia
Philadelphia, PA 19104
Site contact: Samantha Gogel · Gogels@chop.edu
Texas Children's Hospital
Houston, TX 77030
Site contact: Sarah Wisor · sxwisor@texaschildrens.org
University of Virginia
Charlottesville, VA 22903
Site contact: Chelsea Masterson
Childrens Hospital of the King's Daughters
Norfolk, VA 23510
Site contact: Erika Paradiso · Erika.Paradiso@chkd.org
Study contacts (from the official record)
- Janelle Arrambide · 857-500-7526 · janelle.arrambide@biogen.com